이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

골관절염 또는 연골 손상으로 인한 무릎 통증에 대한 CartiPRO의 장기 연구

2026년 9월 30일 업데이트: DALIM TISSEN Co., Ltd.

골관절염 및/또는 다양한 연골 결손 환자의 무릎 통증 완화를 위한 CartiPRO 주사의 장기적 효능과 안전성: 다기관, 단일맹검, 무작위, 비열등성, 후원자 주도 임상시험

This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee osteoarthritis. The investigational device is administered intra-articularly, with a second injection given 24 weeks after the first dose. Primary and secondary endpoints include changes in pain scores (VAS), functional assessments (WOMAC, SF-36), and safety evaluations over a 36-week period.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

Knee osteoarthritis (OA) is the most common joint disorder, primarily caused by the destruction of articular cartilage. Symptoms typically include joint pain, stiffness, and muscle contraction. According to the World Health Organization, in 2013, an estimated 10-15% of adults over the age of 60 were affected by OA, significantly impacting their quality of life.

Collagen degradation is a key feature of cartilage damage in OA. Collagen-based injectable materials, such as atelocollagen, are being explored as potential therapeutic options to restore collagen and improve clinical outcomes. Unlike other injectable substances like hyaluronic acid or corticosteroids, collagen's stable triple helix structure and long half-life make it more resistant to enzymatic degradation, offering a potentially longer-lasting effect.

Despite this, long-term and repeated use data for atelocollagen injections in knee OA are limited both domestically and internationally. This study aims to provide robust clinical evidence on the efficacy and safety of repeated intra-articular atelocollagen injections for knee pain relief in patients with knee OA.

This is a randomized, single-blind, active-controlled study comparing CartiPRO with Synovian. Subjects with knee OA and symptomatic knee pain will receive the investigational device intra-articularly. A second dose will be administered at 24 weeks. The primary outcome is the change in 100-mm weight-bearing pain (WBP) VAS score at 12 weeks compared to baseline.

Secondary outcomes include VAS changes in WBP, resting pain (RP), motion pain (MP), and night pain (NP) at multiple time points, as well as changes in WOMAC and SF-36 scores. Long-term efficacy will be assessed after re-injection. Safety assessments include adverse events, local reactions, physical examination, vital signs, and laboratory tests.

Study Visits:

Visit 1: Screening Visit 2: First injection (baseline) Visit 3: 2 weeks after injection Visit 4: 4 weeks after injection Visit 5: 12 weeks after injection Visit 6: 24 weeks after injection (second dose) Visit 7: 36 weeks after first injection

연구 유형

중재적

등록 (추정된)

194

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Bundang-gu
      • Seongnam-si, Bundang-gu, 대한민국, 13620
        • Seoul National University Bundang Hospital
      • Seoul, Bundang-gu, 대한민국, 13496
        • CHA Bundang Medical Center
    • Eunpyeong-gu
      • Seoul, Eunpyeong-gu, 대한민국, 03312
        • The Catholic University of Korea Eunpyeong St. Mary's Hospital
    • Namdong-gu
      • Seoul, Namdong-gu, 대한민국, 21565
        • Gachon University Gil Hospital
    • Seochogu
      • Seoul, Seochogu, 대한민국, 06591
        • The Catholic University of Korea Seoul St. Mary's Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

19년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

  • Age 19 years and older

  • Diagnosed with unilateral or bilateral knee osteoarthritis according to American College of Rheumatology (ACR) criteria, with at least 3 of the following 6 features:

    • Age ≥50 years
    • Morning stiffness <30 minutes
    • Crepitus on active motion
    • Bony tenderness
    • Bony enlargement
    • No palpable warmth
  • Radiographic evidence of Kellgren-Lawrence grade I, II, or III osteoarthritis within 6 months prior to screening or at screening visit

  • Weight-bearing pain Visual Analogue Scale (VAS) score ≥40 mm in at least one knee joint at screening

  • Able to walk without assistive devices (walkers or canes), OR if using a walking aid routinely for past 6 months, able to continue using the same device throughout the study

  • Able to understand and complete efficacy assessment questionnaires

  • Willing and able to provide written informed consent

Exclusion Criteria

  • Body Mass Index (BMI) ≥32 kg/m²
  • Chronic inflammatory joint disease (e.g., rheumatoid arthritis)
  • Inflammatory joint disease (e.g., septic arthritis)
  • Secondary knee osteoarthritis due to ochronosis, hemochromatosis, or systemic disease
  • Painful musculoskeletal conditions (e.g., Sudeck's atrophy, Paget's disease, herniated intervertebral disc)
  • Polyarticular disease with severe osteoarthritis in other joints (e.g., hip) that may affect knee pain evaluation
  • Radiographic evidence of definite loss of patellofemoral joint space
  • Moderate to severe joint effusion confirmed by positive patellar tap test or equivalent
  • History of myocardial infarction, congestive heart failure, other serious cardiac disease, or uncontrolled hypertension (≥140/90 mmHg despite treatment with ≥3 antihypertensive agents)
  • History of autoimmune disease
  • Active infection requiring parenteral antibiotics
  • History of psychiatric disorder or epilepsy
  • Cancer diagnosis within 5 years prior to screening
  • Uncontrolled type 1 or type 2 diabetes mellitus (HbA1c >7%)
  • Surgical procedures (including arthroscopy) on target knee within 1 year (surgery on contralateral knee or hip may be exclusionary if it could affect target knee assessment)
  • Intra-articular corticosteroid injection into target knee within 12 weeks
  • Systemic corticosteroid use within 4 weeks (topical and inhaled corticosteroids permitted)
  • Surgery or radiation therapy to knee joint within 12 weeks, or not fully recovered from side effects
  • Immunosuppressive therapy (e.g., Cyclosporine A, Azathioprine) within 6 weeks
  • Intra-articular injections (e.g., hyaluronic acid) into knee joint within 6 months
  • Prohibited concomitant medications within 2 weeks (unless washout period is adequate)
  • Anticoagulants (e.g., warfarin, NOACs), antiplatelet agents (e.g., aspirin >100 mg/day, clopidogrel; low-dose aspirin ≤100 mg/day permitted), thrombolytic agents (e.g., urokinase, alteplase), or Vitamin E >1000 IU/day within 2 weeks (unless adequate washout)
  • Habitual use (≥3 months) of psychoactive drugs or narcotic analgesics that may affect pain perception
  • History of cell therapy or gene therapy to target joint
  • Planned cell therapy or gene therapy to target joint
  • Abnormal laboratory values at screening:
  • ALT, AST, BUN, or serum creatinine >2× upper limit of normal
  • Engaged in high-intensity aerobic or heavy anaerobic exercise that may affect the knee joint
  • Dermatological disease at injection site or site deemed unsuitable for injection
  • Ligament instability of Grade II or higher in target knee (Grade 0: none; Grade I: 0-5 mm; Grade II: 5-10 mm; Grade III: >10 mm)
  • Known hypersensitivity to investigational product or its components
  • Pregnant or breastfeeding women
  • Women or men of childbearing potential unwilling to use acceptable contraception during study (acceptable methods: intrauterine device, tubal ligation, sterilization surgery, condom or diaphragm with spermicide, natural family planning)
  • Participation in another clinical trial within 4 weeks
  • Cognitive impairment or dementia preventing informed consent
  • Any other condition that makes the subject unsuitable for study participation per investigator judgment

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Study Group

Group applied with CartiPRO

Clinical subjects are enrolled after the investigator confirms eligibility, and subjects in the study group receive treatment Dalim Tissen's CartiPRO.

Intra-articular medical device injection at baseline and Week 12; final assessment at Week 36.

활성 비교기: Control group

Group applied with Synovian®

Clinical subjects are enrolled after the investigator confirms eligibility, and subjects in the study group receive treatment Synovian®. Intra-articular medical device injection at baseline and Week 12; final assessment at Week 36.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change from baseline in 100-mm Weight-Bearing Pain (WBP) Visual Analogue Scale (VAS) score (0-100 mm)
기간: at week 12 after the first administration

The change from baseline in Weight-Bearing Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at week 12 after the first administration

2차 결과 측정

결과 측정
측정값 설명
기간
Change from Baseline in Weight-Bearing Pain Visual Analogue Scale Score (0-100 mm)
기간: at Weeks 2, 4, and 24 after the first administration

The change from baseline in Weight-Bearing Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Weeks 2, 4, and 24 after the first administration
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index Total and Subscale Scores
기간: at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index will be assessed for the pain, stiffness, and physical function subscales, as well as the total score. Each item is rated from 0 to 4, where 0 indicates no symptoms and 4 indicates extreme symptoms. Subscale scores are calculated by summing item scores, and the total score is calculated as the sum of the subscale scores. Higher scores indicate worse symptoms and poorer function.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Baseline in 36-Item Short Form Health Survey Domain Scores (SF-36)
기간: at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in the 36-Item Short Form Health Survey (SF-36) will be assessed using the eight domain scores: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain score ranges from 0 to 100, where higher scores indicate better health status/quality of life.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Baseline in Rest Pain Visual Analogue Scale Score (0-100 mm)
기간: at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in Rest Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate worse pain.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Baseline in Motion Pain Visual Analogue Scale Score (0-100 mm)
기간: at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in Motion Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Baseline in Night Pain Visual Analogue Scale Score (0-100 mm)
기간: at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in Night Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Week 24 (Re-administration) in Weight-Bearing Pain Visual Analogue Scale Score (0-100 mm)
기간: at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in Weight-Bearing Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain.Higher scores indicate worse pain.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in Rest Pain Visual Analogue Scale Score (0-100 mm)
기간: at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in Rest Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain.Higher scores indicate worse pain.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in Motion Pain Visual Analogue Scale Score (0-100 mm)
기간: at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in Motion Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in Night Pain Visual Analogue Scale Score (0-100 mm)
기간: at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in Night Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in Western Ontario and McMaster Universities Osteoarthritis Index Total and Subscale Scores
기간: at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in the Western Ontario and McMaster Universities Osteoarthritis Index will be assessed for the pain, stiffness, and physical function subscales, as well as the total score. Each item is rated from 0 to 4, where 0 indicates no symptoms and 4 indicates extreme symptoms. Subscale scores are calculated by summing item scores, and the total score is calculated as the sum of the subscale scores. Higher scores indicate worse symptoms and poorer function.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in 36-Item Short Form Health Survey Domain Scores (SF-36)
기간: at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in the 36-Item Short Form Health Survey (SF-36) will be assessed using the eight domain scores: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain score ranges from 0 to 100. Higher scores indicate better health status/quality of life.

at Week 36 (12 weeks after re-administration)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Yong In, Ph.D, The Catholic University of Korea

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 7월 3일

기본 완료 (추정된)

2026년 12월 1일

연구 완료 (추정된)

2027년 6월 1일

연구 등록 날짜

최초 제출

2025년 11월 19일

QC 기준을 충족하는 최초 제출

2025년 11월 24일

처음 게시됨 (실제)

2025년 12월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • DLTS_05

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

Undecided. The plan for sharing individual participant data has not yet been determined.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .